New insights into retrotransposon-derived DNA zip codes in myeloma cells

A new editorial was published in Oncoscience (Volume 11) on July 13, 2024, entitled, "Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization."

The complex interplay between extracellular genetic material and the tumor's genetic landscape presents a significant challenge in grasping cancer evolution, tumor genetic heterogeneity, and treatment response. Earlier research has revealed the role of circulating tumor DNA (ctDNA) in mediating the gene expression among cancer cells, offering new insights into a previously under-explored aspect of genetic exchange in human malignancies.

In this editorial, researchers Pavan Kumar Puvvula, Anthony Johnson, and Leon Bernal-Mizrachi from Kodikaz Therapeutic Solutions, Inc. and Winship Cancer Institute of Emory University delve into the findings of several studies that elucidate the mechanisms underlying ctDNA-driven gene transfer (GT) and its potential implications for cancer biology and therapy.

"GT is a fascinating evolutionary phenomenon observed in lower species and humans, albeit with differing impacts and mechanisms."

This research highlights the importance of retrotransposon-derived DNA zip codes in myeloma cell biology and their interactions with the tumor microenvironment.

"Collaboration between academia, industry, and regulatory agencies will be essential for translating zip-code technology from the bench to the bedside and realizing its full potential in improving patient outcomes and advancing human health."

Source:
Journal reference:

Puvvula, P. K., et al. (2024). Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization. Oncoscience. doi.org/10.18632/oncoscience.606.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals tumor and immune cell interactions in craniopharyngiomas